m+Medelevator.RU
← Поиск публикаций
Science translational medicine · 2025

FcγR-targeted tuftsin clusters rejuvenate macrophages in preclinical sepsis-associated secondary infection.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Qing Guangchao, Zhang Yuxuan, Wang Yongchao, Li Xianlei, Luo Ting, Zhang Fuxue, Ni Qiankun, Hu Runjing, Shan Shaobo, Zhang Hong, Yuan Rui, Gan Yaling, Liang Xing-Jie, Luo Yang

Аннотация

Sepsis-associated secondary infection often leads to a high mortality rate. Dysfunctional macrophages are primary contributors to inadequate antimicrobial defense in patients with sepsis-associated immunosuppression. Rejuvenating macrophage antibacterial capacity is beneficial for host defense against secondary infection. Here, we developed "BATMAN" (bacteria-targeted transformable macrophage nanorejuvenator), a self-assembling peptide nanoparticle to tackle sepsis-associated secondary infection by coordinating the arrest of invasive bacteria and rejuvenation of dysfunctional macrophages. BATMAN comprises a bacteria-targeting ubiquicidin peptide domain, bacterial lipase-sensitive cholesteryl hemisuccinate, an assembly-driving FFVLK domain, and the immunoglobulin G-derived tuftsin peptide. Upon activation by bacterial lipase, the particles undergo an inside-out transformation and assembly to expose and cluster the concealed tuftsin peptides for interaction with macrophage Fcγ receptors. Interaction of tuftsin clusters with macrophage Fcγ receptors enhanced bacterial phagocytosis and drove macrophage repolarization. In a cecal slurry-induced septic mouse model with secondary pulmonary infection, BATMAN treatment improved survival rates and rejuvenated the sepsis-compromised immune response to address polymicrobial- and multidrug-resistant pathogen-induced pulmonary infections. These findings suggest that BATMAN holds promise for further development as a therapeutic alternative for sepsis-associated secondary infection.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты